Edition:
United Kingdom

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

20.28EUR
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
€20.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
379,269
52-wk High
€20.72
52-wk Low
€9.93

Latest Key Developments (Source: Significant Developments)

Ablynx 9-month revenues decrease to 44.7 million euros ​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - ABLYNX NV : :9 MONTH REVENUES OF EUR 44.7 MILLION (2016: EUR 68.9 MILLION)​.9 MONTH ‍OPERATING LOSS OF EUR 42.1 MILLION (2016: EUR 13.6 MILLION)​.‍9 MONTH NET CASH BURN OF EUR 26.9 MILLION (2016: EUR 44.1 MILLION)​.9 MONTH ‍CASH POSITION OF EUR 208.6 MILLION (2016: EUR 263.6 MILLION)​.‍9 MONTH ENDED WITH NET LOSS OF EUR 45.8 MILLION (2016: NET PROFIT OF EUR 10.9 MILLION)​.  Full Article

Ablynx announces full exercise of underwriters' option to purchase additional shares
Friday, 27 Oct 2017 

Oct 27 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD.‍GREENSHOE OPTION GRANTED TO UNDERWRITERS FOR PURCHASE OF UP TO AN ADDITIONAL 1,714,500 NEW ORDINARY SHARES​.‍GREENSHOE EXERCISE BRINGS TOTAL GROSS PROCEEDS FOR OFFERING TO APPROXIMATELY $230 MILLION (EUR 195 MILLION)​.  Full Article

Ablynx ADS open at $17.85 in debut, 2 pct above IPO price ‍​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - :Ablynx ADS open at $17.85 in debut on the NASDAQ versus IPO price of $17.50 per ADS‍‍​.  Full Article

Ablynx prices $200 mln IPO in the United States
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Ablynx NV : :Ablynx prices $200 million initial public offering in the United States.Ablynx NV - ‍prices us IPO totaling $200 million proceeds from sale of 11.43 million shares in form of American depositary shares at price of $17.50/ADS​.  Full Article

Ablynx NV now sees IPO of up to 9.5 mln ordinary shares
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Ablynx NV :Ablynx NV now sees IPO of up to 9.5 million ordinary shares including 8.1 million ordinary shares in form of American Depositary Shares - sec filing.Ablynx NV now expects initial public offering price of ADSS will be between $17.90 and $19.08 per ADS.Ablynx NV says had previously expected IPO of up to 9.2 million ordinary shares including 7.9 million ordinary shares in form of American Depositary Shares.  Full Article

Ablynx NV offers 9.2 million of its ordinary shares in global offering
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Ablynx Nv :Ablynx NV sees offering of 9.2 million of its ordinary shares in a global offering - SEC filing.Co is offering 7.9 million ordinary shares in form of ADS to investors in the United States and Canada.  Full Article

Ablynx to offer and sell about $175 million of its ordinary shares
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING.‍INTENDS TO OFFER AND SELL ABOUT $175 MILLION OF ITS ORDINARY SHARES IN A GLOBAL OFFERING​.‍BOFA MERRILL LYNCH, J.P. MORGAN AND JEFFERIES ARE ACTING AS JOINT BOOK-RUNNING MANAGERS FOR OFFERING​.‍INVESTORS OTHER THAN QUALIFIED INVESTORS UNDER APPLICABLE LAW WILL NOT BE ELIGIBLE TO PARTICIPATE IN THIS PRIVATE PLACEMENT​.‍BAIRD, BRYAN, GARNIER & CO. AND LADENBURG THALMANN ARE ACTING AS CO-MANAGERS FOR OFFERING​.‍FINAL PRICE PER SHARE OF ORDINARY SHARES TO BE DETERMINED FOLLOWING BOOKBUILDING PROCESS​.  Full Article

Ablynx establishes subsidiary in USA
Monday, 16 Oct 2017 

Oct 16 (Reuters) - ABLYNX NV ::ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER.  Full Article

Ablynx announces positive topline results of Phase III Hercules study of Caplacizumab
Monday, 2 Oct 2017 

Oct 2 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP.‍CAPLACIZUMAB MEETS PRIMARY ENDPOINT AND KEY SECONDARY ENDPOINTS​.‍74% RELATIVE REDUCTION IN PERCENTAGE OF PATIENTS WITH ATTP-RELATED DEATH, A RECURRENCE OF ATTP, OR AT LEAST ONE MAJOR THROMBOEMBOLIC EVENT.‍67% RELATIVE REDUCTION IN PERCENTAGE OF PATIENTS WITH ATTP RECURRENCE DURING OVERALL STUDY PERIOD​.‍NO CAPLACIZUMAB-TREATED PATIENTS HAD REFRACTORY DISEASE​.‍TREND TO FASTER NORMALISATION OF ORGAN DAMAGE MARKERS​.‍SAFETY PROFILE CONSISTENT WITH PHASE II TITAN RESULTS AND MECHANISM OF ACTION​.‍DATA WILL BE USED TO DRIVE REGISTRATION PROCESS FOR CAPLACIZUMAB IN EUROPE AND USA​.‍STATISTICALLY SIGNIFICANT REDUCTION IN TIME TO PLATELET COUNT RESPONSE​.  Full Article

Ablynx H1 net income turns to profit of 22.8 million euros
Thursday, 25 Aug 2016 

Ablynx NV : H1 total revenues were 53.5 million euros ($60.3 million), a 39 pct increase compared with 2015 . H1 operating loss reduced to 2.0 million euros, compared with 7.4 million euros in 2015 . H1 net profit of 22.8 million euros versus loss of 15.2 million euros year ago .Outlook for remainder of year confirmed.  Full Article

BRIEF-Ablynx Reports Additional Clinically Important Benefits Of Caplacizumab

* ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP